

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 16, 2003, 13:53:06 ; Search time 69 Seconds  
(Without alignments)  
42.486 Million cell updates/sec

Title: US-09-914-213-2  
Perfect score: 116  
Sequence: 1 GLEISEINEDEKCECFDDME 22

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: A\_Geneseq\_101002.\*  
2: /SID22/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*  
3: /SID22/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*  
4: /SID22/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*  
5: /SID22/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*  
6: /SID22/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*  
7: /SID22/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*  
8: /SID22/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*  
9: /SID22/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*  
10: /SID22/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*  
11: /SID22/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*  
12: /SID22/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*  
13: /SID22/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*  
14: /SID22/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*  
15: /SID22/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*  
16: /SID22/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*  
17: /SID22/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*  
18: /SID22/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*  
19: /SID22/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*  
20: /SID22/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*  
21: /SID22/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*  
22: /SID22/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*  
23: /SID22/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*  
24: /SID22/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	116	100.0	22	21	AA1980.DAT
2	116	100.0	22	21	AA1981.DAT
3	116	100.0	22	21	AA1982.DAT
4	116	100.0	22	21	AA1983.DAT
5	116	100.0	22	21	AA1984.DAT
6	116	100.0	22	21	AA1985.DAT
7	116	100.0	22	21	AA1986.DAT
8	116	100.0	22	21	AA1987.DAT
9	116	100.0	22	21	AA1988.DAT
10	116	100.0	22	21	AA1989.DAT
11	116	100.0	22	21	AA1990.DAT
12	116	100.0	22	21	AA1991.DAT
13	116	100.0	22	21	AA1992.DAT
14	116	100.0	22	21	AA1993.DAT
15	116	100.0	22	21	AA1994.DAT
16	116	100.0	22	21	AA1995.DAT
17	116	100.0	22	21	AA1996.DAT
18	116	100.0	22	21	AA1997.DAT
19	116	100.0	22	21	AA1998.DAT
20	116	100.0	22	21	AA1999.DAT
21	116	100.0	22	21	AA2000.DAT
22	116	100.0	22	21	AA2001.DAT
23	116	100.0	22	21	AA2002.DAT

11	110	94.8	1479	23	AAU74516
12	110	94.8	1480	12	AA111115
13	110	94.8	1480	12	AA113252
14	110	94.8	1480	12	AA113253
15	110	94.8	1480	12	AA113254
16	110	94.8	1480	12	AA113255
17	110	94.8	1480	12	AA113256
18	110	94.8	1480	12	AA113257
19	110	94.8	1480	12	AA113258
20	110	94.8	1480	12	AA113259
21	110	94.8	1480	12	AA113260
22	110	94.8	1480	12	AA113261
23	110	94.8	1480	12	AA113262
24	110	94.8	1480	12	AA113263
25	110	94.8	1480	12	AA113264
26	110	94.8	1480	12	AA113265
27	110	94.8	1480	12	AA113266
28	110	94.8	1480	12	AA113267
29	110	94.8	1480	12	AA113268
30	110	94.8	1480	12	AA113269
31	110	94.8	1480	12	AA113270
32	110	94.8	1480	12	AA113271
33	110	94.8	1480	12	AA113272
34	110	94.8	1480	12	AA113273
35	110	94.8	1480	12	AA113274
36	110	94.8	1480	12	AA113275
37	110	94.8	1480	12	AA113276
38	110	94.8	1480	12	AA113277
39	110	94.8	1480	12	AA113278
40	110	94.8	1480	12	AA113279
41	110	94.8	1480	12	AA113280
42	110	94.8	1480	12	AA113281
43	110	94.8	1480	12	AA113282
44	110	94.8	1480	12	AA113283
45	110	94.8	1480	12	AA113284

#### ALIGNMENTS

XX	RESULT 1
PT	AA1980.DAT
XX	standard; peptide; 22 AA.
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT
XX	AA1989.DAT
XX	AA1990.DAT
XX	AA1991.DAT
XX	AA1992.DAT
XX	AA1993.DAT
XX	AA1994.DAT
XX	AA1995.DAT
XX	AA1996.DAT
XX	AA1997.DAT
XX	AA1998.DAT
XX	AA1999.DAT
XX	AA2000.DAT
XX	AA2001.DAT
XX	AA2002.DAT
XX	AA1980.DAT
XX	AA1981.DAT
XX	AA1982.DAT
XX	AA1983.DAT
XX	AA1984.DAT
XX	AA1985.DAT
XX	AA1986.DAT
XX	AA1987.DAT
XX	AA1988.DAT

PS Claim 2; Fig 2; 35pp; English.

CC Defects in the cystic fibrosis transmembrane conductance regulator

CC (CFTR), are associated with cystic fibrosis (CF). CFTR is a chloride

CC channel located in the apical membrane of epithelial cells. The present

CC peptide is a fragment of human CFTR. This peptide is useful for

CC activating and opening a CFTR protein by the formation of cAMP regulated

CC chloride channel. This peptide can therefore be used as therapy for CF.

XX

SQ Sequence 22 AA;

Query Match 100.0%; Score 116; DB 21; Length 22;

Best Local Similarity 100.0%; Pred. No. 2e-09;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GLEISEEINEDLKCFDDME 22

DB 1 GLEISEEINEDLKCFDDME 22

RESULT 2

AAB31723

ID AAB31723 standard; Protein; 1480 AA.

XX

AC AAB31723;

XX

DT 30-APR-2001 (first entry)

XX

DE A human cystic fibrosis transmembrane conductance regulator.

XX

XX Arginine-framed tripeptide; AFT; endoplasmic reticulum retention;

KW cystic fibrosis transmembrane conductance regulator; CFTR; hormone;

KW cystic fibrosis; macular dystrophy; stargardt's disease; growth factor;

KW export-incompetent protein; adenine-nucleotide binding cassette protein;

KW ABC protein; immune regulator; adhesion protein; clotting factor;

KW hemostatic regulator; intracellular transport.

XX

OS Homo sapiens.

XX

PN WO200103722-A1.

PD 18-JAN-2001.

XX

PF 07-JUL-2000; 2000WO-US40324.

XX

PR 09-JUL-1999; 99US-0143090.

XX

PR 21-JUL-1999; 99US-0146097.

XX

PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.

XX

PI Riordan JR, Chang X;

XX

PS WPI; 2001-123141/13.

DR

XX

PT Novel cystic fibrosis transmembrane conductance regulator proteins,

XX

XX useful for treating cystic fibrosis have one arginine, in an arginine

XX

XX tripeptide sequence motif, substituted by other amino acid

XX

PS Disclosure; Fig 6; 56pp; English.

XX

XX The present sequence represents a human cystic fibrosis transmembrane

CC conductance regulator (CFTR). Arginine-framed tripeptide (AFT) sequences

CC of CFTR contribute to endoplasmic reticulum (ER) retention or delay in

CC maturation of proteins. The AFT sequences are useful as competitive

CC inhibitors of ER retention. The peptides are useful for treating cystic

CC fibrosis. They are useful for treating a subject having a suspected of

CC having a physiological disorder (e.g. macular dystrophy and stargardt's

CC disease) associated with an export-incompetent protein such as

CC adenine-nucleotide binding cassette (ABC) protein, growth factor, immune

CC regulator, adhesion protein, hormone, clotting factor, hemostatic

CC regulator and their receptors. The AFT peptides are also useful for

CC inducing or increasing intracellular transport of an export-incompetent

CC protein in a cell e.g. a cell surface or secreted protein and preferably

CC export-incompetent CFTR. They are also useful for inhibiting degradation

CC of a secreted or cell surface protein in a cell and for detecting the

CC presence of an export-incompetent protein in a cell.

XX

SQ Sequence 1480 AA;

Query Match 100.0%; Score 116; DB 22; Length 1480;

Best Local Similarity 100.0%; Pred. No. 1.7e-07;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GLEISEEINEDLKCFDDME 22

DB 817 GLEISEEINEDLKCFDDME 838

RESULT 3

ABG17640

ID ABG17640 standard; Protein; 1614 AA.

XX

AC ABG17640;

XX

DT 18-FEB-2002 (first entry)

XX

DE Novel human diagnostic protein #17631.

XX

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;

KW food supplement; medical imaging; diagnostic; genetic disorder.

XX

OS Homo sapiens.

XX

PN WO200175067-A2.

XX

PD 11-OCT-2001.

XX

PR 30-MAR-2001; 2001WO-US08631.

XX

PR 31-MAR-2000; 2000US-0540217.

XX

PR 23-AUG-2000; 2000US-0649167.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Drmanac RT, Liu C, Tang YT;

XX

PS WPI; 2001-639362/73.

XX

DR N-PSDB; AAS81827.

XX

PT New isolated polynucleotide and encoded polypeptides, useful in

XX

XX diagnostics, forensics, gene mapping, identification of mutations

XX

XX responsible for genetic disorders or other traits and to assess

XX

XX biodiversity

XX

PS Claim 20; SEQ ID No 47999; 103pp; English.

XX

XX The invention relates to isolated polynucleotide (I) and

CC polypeptide (II) sequences. (I) is useful as hybridisation probes,

CC polymerase chain reaction (PCR) primers, oligomers) and for chromosome

CC and gene mapping, and in recombinant production of (II). The

CC polynucleotides are also used in diagnostics as expressed sequence tags

CC for identifying expressed genes. (I) is useful in gene therapy techniques

CC to restore normal activity of (II) or to treat disease states involving

CC (II). (II) is useful for generating antibodies against it, detecting or

CC quantitating a polypeptide in tissue, as molecular weight markers and as

CC a food supplement. (II) and its binding partners are useful in medical

CC imaging of sites expressing (II). (I) and (II) are useful for treating

CC disorders involving aberrant protein expression or biological activity.

CC The polypeptide and polynucleotide sequences have applications in

CC diagnostics, forensics, gene mapping, identification of mutations

CC responsible for genetic disorders or other traits to assess biodiversity

CC and to produce other types of data and products dependent on DNA and

CC amino acid sequences. ABG00010-ABG30377 represent novel human

CC diagnostic amino acid sequences of the invention.

CC Note: The sequence data for this patent did not appear in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequences.  
 XX Sequence "1614 AA;  
 SQ  
 Query Match 100.0%; Score 116; DB 22; Length 1614;  
 Best Local Similarity 100.0%; Pred. No. 1.8e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 GLEISEINEEDLKECFDDME 22  
 Db 1531 GLEISEINEEDLKECFDDME 1552  
 RESULT 4  
 ABG14961  
 ID ABG14961 standard; Protein: 1843 AA.  
 AC ABG14961;  
 DT 18-FEB-2002 (first entry)  
 DE Novel human diagnostic protein #14952.  
 XX  
 KW Human: chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 OS Homo sapiens.  
 XX  
 PN WO200175067-A2.  
 PD 11-OCT-2001.  
 XX  
 PF 30-MAR-2001; 2001WO-US08631.  
 XX  
 PR 31-MAR-2000; 2000US-0540217.  
 PR 23-AUG-2000; 2000US-0649167.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 PI Drmanac RT, Liu C, Tang YT;  
 DR WPI: 2001-639362/73.  
 DR N-PSDB: AAS79148.  
 XX  
 PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity -  
 PS Claim 20; SEQ ID NO 45320; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC (II). (II) is useful for generating antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.  
 XX

SQ Sequence 1843 AA;  
 Query Match 100.0%; Score 116; DB 22; Length 1843;  
 Best Local Similarity 100.0%; Pred. No. 2.1e-07;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 GLEISEINEEDLKECFDDME 22  
 Db 1777 GLEISEINEEDLKECFDDME 1798  
 RESULT 5  
 AAR13303  
 ID AAR13303 standard; Protein: 1091 AA.  
 AC AAR13303;  
 DT 14-OCT-1991 (first entry)  
 DE CFTR Y1092X.  
 XX  
 KW Deletion; mutant; diagnosis; antibodies; drug therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key  
 FT Domain  
 FT 81..102  
 FT /label= membrane-spanning\_domain  
 FT 118..138  
 FT /label= membrane-spanning\_domain  
 FT 195..215  
 FT /label= membrane-spanning\_domain  
 FT 221..241  
 FT /label= membrane-spanning\_domain  
 FT 308..328  
 FT /label= membrane-spanning\_domain  
 FT 330..350  
 FT /label= membrane-spanning\_domain  
 FT 860..880  
 FT /label= membrane-spanning\_domain  
 FT 912..932  
 FT /label= membrane-spanning\_domain  
 FT 991..1011  
 FT /label= membrane-spanning\_domain  
 FT 1014..1034  
 FT /label= membrane-spanning\_domain  
 FT 1103..1123  
 FT /label= membrane-spanning\_domain  
 FT 1129..1150  
 FT /label= membrane-spanning\_domain  
 FT 433..584  
 FT /label= ATP-binding\_domain  
 FT 1219..1386  
 FT /label= ATP-binding\_domain  
 FT 50  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 63  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 164  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 168  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 256  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 271  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT 296  
 FT /label= phosphorylation\_site  
 FT /note= "by protein kinases C"  
 FT Modified-site

```

FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 422
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 485
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 501
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 582
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 623
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 641
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 682
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 686
FT /label= phosphorylation_site /note= "by protein kinases C and A"
FT Modified-site 700
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 707
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 712
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 737
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 768
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 788
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 790
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 791
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 795
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 809
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 813
FT /label= phosphorylation_site /note= "by protein kinases A"
FT Modified-site 966
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1058
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1064
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1095
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1178
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1178
FT /label= phosphorylation_site /note= "by protein kinases C"

```

```

FT /note= "by protein kinases C"
FT Modified-site 1211
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1216
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1248
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1299
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1387
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1444
FT /label= phosphorylation_site /note= "by protein kinases C"
FT Modified-site 1455
FT /label= phosphorylation_site /note= "by protein kinases C"

```

```

PN WO9110734-A.
PD 25-JUL-1991.
XX
PF 11-JAN-1991; 91WO-CA00009.
XX
PR 10-JUL-1990; 90CA-2020817.
PR 12-JAN-1990; 90CA-2007699.
PR 01-MAR-1990; 90CA-2011253.
XX
PA (HSCR-) HSC RES DEV CORP.
XX
XX Tsui LC, Rommens JM, Kerem B:
PI WPT; 1991-238022/32.
XX DR N-PDB; AAQ13066.
XX

```

```

PT Mutant cystic fibrosis trans-membrane conductance regulator gene
PT - used for producing prods. for diagnosis, screening and therapy
PT of cystic fibrosis
XX
PS Claim 20; Page 124; 178pp; English.
XX

```

```

CC In the LY1092X mutation a C to A change is detected at nucleotide
CC position 3408. This would result in protein synthesis termination
CC at amino position 1092. Hence the amino acid Tyr is not present
CC in the truncated polypeptide.
CC The mutant CF gene when expressed in cells of the human body, is
CC associated with altered cell function which correlates with the
CC genetic disease cystic fibrosis.
CC See also AAQ13053-72.
XX

```

```

XX Sequence 1091 AA:

```

```

SQ
Query Match 94.8%; Score 110; DB 12; Length 1091;
Best Local Similarity 95.5%; Pred. No. 8.2e-07;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1 GLEISEINEDIKCFDDME 22
DB 817 GLEISEINEDIKCFDDME 838

```

```

RESULT 6
AAR13308
ID AAR13308 standard; Protein; 1190 AA.
XX
AC AAR13308;
XX
DT 14-OCT-1991 (first entry)

```

XX	DE	CFRR 3659 del C.
XX	Deletion; mutant; diagnosis; antibodies; drug therapy.	
KW	Homo sapiens.	
OS		
XX		
FH	Key	Location/Qualifiers
FT	Domain	81..102
FT	Domain	/label- membrane-spanning_domain
FT	Domain	118..138
FT	Domain	/label- membrane-spanning_domain
FT	Domain	195..215
FT	Domain	/label- membrane-spanning_domain
FT	Domain	221..241
FT	Domain	/label- membrane-spanning_domain
FT	Domain	308..328
FT	Domain	/label- membrane-spanning_domain
FT	Domain	330..350
FT	Domain	/label- membrane-spanning_domain
FT	Domain	860..880
FT	Domain	/label- membrane-spanning_domain
FT	Domain	912..932
FT	Domain	/label- membrane-spanning_domain
FT	Domain	991..1011
FT	Domain	/label- membrane-spanning_domain
FT	Domain	1014..1034
FT	Domain	/label- membrane-spanning_domain
FT	Domain	433..584
FT	Modified-site	/label- Atp-binding_domain
FT	Modified-site	50
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	63
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	164
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	168
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	256
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	271
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	296
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	422
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases A"
FT	Modified-site	485
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	501
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	582
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	623
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	641
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases A"
FT	Modified-site	682
FT	Modified-site	/label- phosphorylation_site
FT	Modified-site	/note- "by protein kinases C"
FT	Modified-site	686

FT	/label= phosphorylation_site
FT	/note= "by protein kinases C and A"
FT	700
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	707
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	712
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	737
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	768
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	788
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	790
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	791
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	795
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	809
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	813
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases A"
FT	966
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	1058
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	1064
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	1095
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
FT	1178
FT	Modified-site
FT	/label= phosphorylation_site
FT	/note= "by protein kinases C"
XX	
PX	
PN	WO9110734-A.
XX	
PD	25-JUL-1991.
XX	
PF	11-JAN-1991; 91WQ-CA00009.
XX	
PR	10-JUL-1990; 90CA-2020617.
PR	12-JAN-1990; 90CA-2007699.
PR	01-MAR-1990; 90CA-2011253.
XX	
PA	(HSCR-) HSC RES DEV CORP.
XX	
PI	Tsuji LC, Rommens JM, Kerem B;
XX	WPl; 1991-238022/32.
DR	N-PSDB; AAQ13072.
XX	
PT	Mutant cystic fibrosis trans-membrane conductance regulator gene
PT	- used for producing prods. for diagnosis, screening and therapy
of	cystic fibrosis
xx	
S5	Claim 20; Page 124; 178pp; English.

Claim 20; Page 124; 178pp; English.

XX 3659 del C is a frameshift mutation in exon 19.  
 CC The 3659 del C mutation results in a shortened polypeptide  
 CC significantly different from the single amino acid deletions or  
 CC alterations.  
 CC The mutant CF gene when expressed in cells of the human body, is  
 CC associated with altered cell function which correlates with the  
 CC genetic disease cystic fibrosis.  
 CC See also AAQ13053-72.

XX Sequence 1190 AA;

Query Match 94.8%; Score 110; DB 12; Length 1190;

Best Local Similarity 95.5%; Pred. No. 9e-07; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEEDLKECFDDME 22  
 DB 817 GLEISEINEEDLKECFDDME 838

# RESULT 7

AAV33968 standard; Protein; 1476 AA.

AC AAV33968;

DE 26-MAY-2000 (first entry)

DE CFTR protein sequence.

XX AAV vector; inverted terminal repeat; ITR; gene therapy; CFTR; TK gene;  
 KM cystic fibrosis transmembrane conductance regulator; cystic fibrosis;  
 KM promoter; HSV; thymidine kinase; chromosome 7q31.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 1150 /note="encoded by AGC"

XX WO943789-A1.

PD 02-SEP-1999.

XX 25-FEB-1999; 99WO-US04212.

XX 25-FEB-1998; 98US-0075980.

XX (REGC ) UNIV CALIFORNIA.

PI Dong J, Kan YW;

XX WPI; 1999-550866/46.

DR N-PSDB; AAZ11643.

XX Efficient AAV vectors useful in gene therapy protocols for the

XX treatment of cystic fibrosis

XX Example 1; Page 33; 34pp; English.

XX The invention provides efficient AAV vectors with improved capacity for  
 CC DNA due to the removal of all nucleic acid sequences that are not  
 CC essential for replication (to leave just 2 inverted terminal repeat  
 CC sequences (ITRs)). The AAV vectors may be used for the delivery of  
 CC therapeutic nucleic acids in gene therapy protocols. In particular,  
 CC they may be used to deliver cystic fibrosis (CF) transmembrane  
 CC conductance regulator (CFTR) polynucleotides to the respiratory tract  
 CC of CF patients to rectify mutations in the patients own CFTR genes and  
 CC restore normal function to the chloride channel for replication,  
 CC vector lacks all nucleic acids that are not essential for replication,  
 CC therefore giving it a greater capacity for exogenous DNA and hence  
 CC improving the efficiency with which it transfects cells. The AAV vectors

CC of the invention can efficiently and persistently transfer CFTR  
 CC polynucleotides to the airway epithelium of CF patients without any  
 CC adverse side effects. The present sequence represents the CFTR protein.

XX Sequence 1476 AA;

Query Match 94.8%; Score 110; DB 20; Length 1476;

Best Local Similarity 95.5%; Pred. No. 1.1e-06; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEEDLKECFDDME 22  
 DB 817 GLEISEINEEDLKECFDDME 838

# RESULT 8

AAR11602 standard; Protein; 1479 AA.

AC AAR11602;

DE 22-MAY-1991 (first entry)

XX Mutant cystic fibrosis transmembrane conductance regulatory protein.  
 DE Cystic fibrosis; transmembrane conductance regulatory protein; CFTR;  
 KM diagnosis; mutant.

XX Homo sapiens.

XX Key Location/Qualifiers

FT 81..102 /label=potential\_membrane-spanning\_segment

FT 118..138 /label=potential\_membrane-spanning\_segment

FT 195..215 /label=potential\_membrane-spanning\_segment

FT 221..241 /label=potential\_membrane-spanning\_segment

FT 308..328 /label=potential\_membrane-spanning\_segment

FT 330..350 /label=potential\_membrane-spanning\_segment

FT 859..879 /label=potential\_membrane-spanning\_segment

FT 911..931 /label=potential\_membrane-spanning\_segment

FT 990..1010 /label=potential\_membrane-spanning\_segment

FT 1013..1033 /label=potential\_membrane-spanning\_segment

FT 1102..1122 /label=potential\_membrane-spanning\_segment

FT 1128..1149 /label=potential\_membrane-spanning\_segment

FT 433..583 /label=potential\_membrane-spanning\_segment

FT 1218..1385 /label=putative\_ATP-binding\_folds

FT 50..50 /label=protein\_kinase\_C-phosphorylation\_site

FT 63..63 /label=protein\_kinase\_C-phosphorylation\_site

FT 164..164 /label=protein\_kinase\_C-phosphorylation\_site

FT 168..168 /label=protein\_kinase\_C-phosphorylation\_site

FT 256..256 /label=protein\_kinase\_C-phosphorylation\_site

FT 271..271 /label=protein\_kinase\_C-phosphorylation\_site

FT 296..296 /label=protein\_kinase\_C-phosphorylation\_site

```

FT M1sc-difference 485..485
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 501..501
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 581..581
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 622..622
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 681..681
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 685..685
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 706..706
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 779..779
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 790..790
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 808..808
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 965..965
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1057..1057
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1063..1063
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1094..1094
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1177..1177
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1210..1210
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1215..1215
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1247..1247
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1298..1298
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1386..1386
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1443..1443
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 1454..1454
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 422..422
FT /label= protein_kinase_C.phosphorylation_site
FT M1sc-difference 640..640
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 685..685
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 699..699
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 711..711
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 736..736
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 767..767
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 787..787
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 796..796
FT /label= protein_kinase_A.phosphorylation_site
FT M1sc-difference 812..812
FT /label= protein_kinase_A.phosphorylation_site
FT
FT
XX WO9102796-A.
XX
XX 07-MAR-1991.
XX
XX 20-AUG-1990; 90MO-CA00267.
XX
XX 31-AUG-1989; 89US-0401609.
XX
XX 22-AUG-1989; 89US-0396894.
PR

```

```

PR 24-AUG-1989; 89US-0399945.
XX
XX (HSCR-) HSC RES DEV CORP.
PA (UNMI) UNIV OF MICHIGAN.
XX
XX Tsui LC, Riordan JR, Collins FS, Rommens JM, Iannuzzi MC;
PI Kerem BS, Drummler ML, Buchwald M;
XX WPI; 1991-087280/12.
DR N-PSDB; AAQ11371.
XX
XX Cystic fibrosis gene - used to produce prods. for screening,
PT detection, diagnosis, therapy and studying cystic fibrosis
XX
XX Disclosure: Fig 1; 163pp; English.
XX
XX This sequence lacks amino acid Phe 508 of the normal protein, as a
CC result of a 3bp deletion in the nucleotide sequence.
CC The CF gene and its gene prod., nucleic acid probes and antibodies
CC to the gene prod. can be used for screening and detection of CF
CC carriers, CF diagnosis, prenatal CF screening and diagnosis,
CC and gene and drug therapy. The prods. can also be used to develop
CC improved methods of treatment and to study the disease.
CC See AAQ11046 for the normal CF gene and AAQ11047-48 for CF probes.
XX
SQ Sequence 1479 AA:
OY
OY 1 GLEISERINEDLKECFDME 22
DB 816 GLEISERINEDLKECFDME 837
RESULT 9
ID AAR13231 standard; Protein; 1479 AA.
XX
XX AAR13231;
AC
XX 14-OCT-1991 (first entry)
DE
XX CFTR delta I507.
XX
XX Deletion; mutant; diagnosis; antibodies; drug therapy;
KW ATP-binding domain.
XX
XX Homo sapiens.
XX
XX
FH Key
FH Location/Qualifiers
FT Domain 81..102 /label= membrane-spanning_domain
FT Domain 118..138 /label= membrane-spanning_domain
FT Domain 195..215 /label= membrane-spanning_domain
FT Domain 221..241 /label= membrane-spanning_domain
FT Domain 308..328 /label= membrane-spanning_domain
FT Domain 330..350 /label= membrane-spanning_domain
FT Domain 359..879 /label= membrane-spanning_domain
FT Domain 911..931 /label= membrane-spanning_domain
FT Domain 990..1010 /label= membrane-spanning_domain
FT Domain 1013..1033 /label= membrane-spanning_domain
FT Domain 1102..1122 /label= membrane-spanning_domain
FT

```





CC results in the loss of an isoleucine residue from the putative  
 CC CFTR, within the same ATP-binding domain where deltaF508 resides,  
 CC but it is not evident whether this deleted amino acid corresponds  
 CC to the position 506 or 507. Since the 506 and 507 positions are  
 CC repeats, it is at present impossible to determine in which position  
 CC the deletion occurs.  
 CC The mutant CF gene when expressed in cells of the human body, is  
 CC associated with altered cell function which correlates with the  
 CC genetic disease cystic fibrosis.  
 CC See also AA013053-72.

SO Sequence 1479 AA;

Query Match 94.8%; Score 110; DB 12; Length 1479;  
 Best Local Similarity 95.5%; Pred. No. 1.1e-06;  
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEEDLKECFDDME 22  
 |||||  
 DB 816 GLEISEINEEDLKECLFDDME 837

RESULT 10

ID AA02279 standard; Protein; 1479 AA.

AA02279;

08-JUL-1999 (first entry)

DeltaF508 cystic fibrosis transmembrane conductance regulator.

KW Flavone; isoflavone; resveratrol; ascorbic acid; ascorbate salt;  
 KW dehydroascorbic acid; chloride transport; epithelial cell;  
 KW cystic fibrosis; chloride ion conductance;  
 KW cystic fibrosis transmembrane conductance regulator; CFTR;  
 KW chronic bronchitis; asthma; intestinal constipation.

OS Homo sapiens.

PN MO9918953-A1.

PD 22-APR-1999.

PF 16-OCT-1998; 98MO-US21887.

PR 16-OCT-1997; 97US-0951912.

PA (CHIL-) CHILDREN'S HOSPITAL OAKLAND RES INST.

PI Fischer HB, Illek B;

DR WPI: 1999-277427/23.

DR N-PSDB; AAX35553.

PT Use of flavones and isoflavones - for stimulating chloride transport  
 PT in epithelial cells and treating cystic fibrosis

PS Disclosure; Page 73-80; 97pp; English.

CC The specification describes compounds comprising flavones/isoflavones,  
 CC resveratrol, ascorbic acid, ascorbate salts and/or dehydroascorbic  
 CC acid which can be used for stimulating chloride transport in epithelial  
 CC cells and treating cystic fibrosis. The compounds can be used to  
 CC increase chloride ion conductance in airway epithelial cells or  
 CC intestinal, pancreas, gallbladder, sweat duct, salivary gland or mammary  
 CC epithelial cells. The compounds are useful for treating a patient with  
 CC cystic fibrosis, where the patient's cystic fibrosis transmembrane  
 CC conductance regulator (CFTR) protein has a deletion at position 508 or  
 CC point mutation at 551. They may also be used for treating chronic  
 CC bronchitis, asthma and intestinal constipation. The present sequence  
 CC represents a human CFTR protein with a F508 deletion mutation.

SO Sequence 1479 AA;

Query Match 94.8%; Score 110; DB 20; Length 1479;  
 Best Local Similarity 95.5%; Pred. No. 1.1e-06;  
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEEDLKECFDDME 22  
 |||||  
 DB 816 GLEISEINEEDLKECLFDDME 837

RESULT 11

ID AA074516 standard; Protein; 1479 AA.

AA074516;

23-APR-2002 (first entry)

Human delta-F508-CFTR mutant polypeptide.

KW Human; cystic fibrosis transmembrane conductance regulator; CFTR;  
 KW Flavone; isoflavone; chloride transport; epithelial tissue; mucus;  
 KW cystic fibrosis; chronic bronchitis; asthma; delta-F508-CFTR; protein.

OS Homo sapiens.

PN US6329422-B1.

PD 11-DEC-2001.

PF 16-OCT-1998; 98US-0174077.

PR 16-OCT-1997; 97US-0951912.

PA (CHIL-) CHILDREN'S HOSPITAL OAKLAND RES INST.

PI Fischer H, Illek B;

DR WPI: 2002-105224/14.

DR N-PSDB; AAS20529.

PT Pharmaceutical composition for the treatment of cystic fibrosis  
 PT comprises flavones or isoflavones

PS Disclosure; Column 37-44; 50pp; English.

CC The invention relates to a pharmaceutical composition comprising one or  
 CC more compounds such as flavones or isoflavones, capable of stimulating  
 CC chloride transport in epithelial tissues, for treatment of cystic  
 CC fibrosis and other diseases associated with excessive accumulation of  
 CC mucus, e.g. chronic bronchitis and asthma. The active compound increases  
 CC expression of a cystic fibrosis transmembrane conductance regulator  
 CC (CFTR) in an epithelial cell and/or acts as a chemical chaperone that  
 CC increases trafficking of a CFTR to a plasma membrane in an epithelial  
 CC cell. This sequence represents the human delta-F508-CFTR mutant  
 CC polypeptide of the invention.

SO Sequence 1479 AA;

Query Match 94.8%; Score 110; DB 23; Length 1479;  
 Best Local Similarity 95.5%; Pred. No. 1.1e-06;  
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEEDLKECFDDME 22  
 |||||  
 DB 816 GLEISEINEEDLKECLFDDME 837

RESULT 12

ID AAR11115 standard; Protein; 1480 AA.

AC AAR1115;  
 XX 22-MAY-1991 (first entry)  
 DE Cystic fibrosis transmembrane conductance regulatory protein.  
 XX Cystic fibrosis; transmembrane conductance regulatory protein; CFTR;  
 KM diagnosis.  
 XX Homo sapiens.  
 OS  
 XX  
 FH Key  
 FT Location/Qualifiers  
 FT 81..102  
 FT /label= potential\_membrane-spanning\_segment  
 FT 118..138  
 FT /label= potential\_membrane-spanning\_segment  
 FT 195..215  
 FT /label= potential\_membrane-spanning\_segment  
 FT 221..241  
 FT /label= potential\_membrane-spanning\_segment  
 FT 308..328  
 FT /label= potential\_membrane-spanning\_segment  
 FT 330..350  
 FT /label= potential\_membrane-spanning\_segment  
 FT 860..880  
 FT /label= potential\_membrane-spanning\_segment  
 FT 912..932  
 FT /label= potential\_membrane-spanning\_segment  
 FT 991..1011  
 FT /label= potential\_membrane-spanning\_segment  
 FT 1014..1034  
 FT /label= potential\_membrane-spanning\_segment  
 FT 1103..1123  
 FT /label= potential\_membrane-spanning\_segment  
 FT 1129..1150  
 FT /label= potential\_membrane-spanning\_segment  
 FT 433..584  
 FT /label= putative\_ATP-binding\_folds  
 FT 1219..1386  
 FT /label= putative\_ATP-binding\_folds  
 FT 50..50  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 63..63  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 164..164  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 168..168  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 256..256  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 271..271  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 296..296  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 485..485  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 501..501  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 582..582  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 623..623  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 682..682  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 686..686  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 707..707  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 790..790  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 791..791  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT Misc-difference 809..809

FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT Misc-difference 966..966  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1058..1058  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1064..1064  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1095..1095  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1178..1178  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1211..1211  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1216..1216  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1248..1248  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1299..1299  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1387..1387  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1444..1444  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 1455..1455  
 FT /label= protein\_kinase\_C-phosphorylation\_site  
 FT 422..422  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 641..641  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 686..686  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 700..700  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 712..712  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 737..737  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 768..768  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 788..788  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 795..795  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 813..813  
 FT /label= protein\_kinase\_A-phosphorylation\_site  
 FT 508..508  
 FT /label= mutation  
 FT /note= "residue is deleted in the CFTR mutant"  
 XX  
 PN WO9102796-A.  
 XX  
 XX 07-MAR-1991.  
 PD  
 XX 20-AUG-1990; 90WO-CA00267.  
 PF  
 XX 31-AUG-1989; 89US-0401609.  
 PR 22-AUG-1989; 89US-0396894.  
 PR 24-AUG-1989; 89US-0399945.  
 XX  
 PA (HSCR-) HSC RES DEV CORP.  
 PA (UNMI ) UNIV OF MICHIGAN.  
 XX  
 XX Tsui LC, Riordan JR, Collins FS, Rommens JM, Iannuzzi MC;  
 PI Kerem BS, Drumml ML, Buchwald M;  
 XX  
 DR P-PSDB; AAR1115.  
 XX  
 XX Cystic fibrosis gene - used to produce prods. for screening,  
 PT detection, diagnosis, therapy and studying cystic fibrosis  
 XX  
 PS Disclosure; Fig 1; 163pp; English.  
 XX







[illegible]

```

XX WO9110734-A.
PN
XX
XX 25-JUL-1991.
PD
XX
XX 11-JAN-1991; 91WO-CA00009.
PE
XX
XX 10-JUL-1990; 90CA-2020817.
PR
XX 12-JAN-1990; 90CA-2007699.
PR
XX 01-MAR-1990; 90CA-2011253.
XX
PA (HSCR-) HSC RES DEV CORP.
XX
XX Tsui LC, Rommens JM, Kerem B;
PI
XX WPI; 1991-238022/32.
DR
XX N-PSDB; AAQ13056.
XX
XX Mutant cystic fibrosis trans-membrane conductance regulator gene
PT -used for producing prods. for diagnosis, screening and therapy
XX of cystic fibrosis
XX
XX Claim 20; Page 124; 178pp; English.
PS
XX
XX The G178R mutation in exon 5 involves a G to A transition at
CC nucleotide position 664 resulting in a Gly to Arg change at amino
CC acid position 178.
CC The mutant CF gene when expressed in cells of the human body, is
CC associated with altered cell function which correlates with the
CC genetic disease cystic fibrosis.
CC See also AAQ13053-72.
XX
XX
SO Sequence 1480 AA;

Query Match          94.8%; Score 110; DB 12; length 1480;
Best Local Similarity 95.5%; Pred. No. 1,1e-06;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 GLEISEINEDLKECFDDME 22
   |||||
Db 817 GLEISEINEDLKECFDDME 838

```

Search completed: July 16, 2003, 14:01:12  
 Job time : 70 secs

